Abbott Laboratories’ adult nutrition business is poised to drive modest growth in Q4, supported by the recent launches of new Ensure formulations and an expanded Glucerna product line. Company data indicates that the adult nutrition division contributed approximately 12% of total revenues in Q3, with year-over-year segment sales growth estimated at 4%. Ensure’s reformulated high-protein shake recorded a 15% uptick in unit volumes during the first two months post-launch, while Glucerna’s carbohydrate-control portfolio achieved a 10% increase in prescriptions from healthcare providers in the same period.

In Q3 2025, Abbott Laboratories reported normalized earnings per share of $1.30, in line with management guidance, while consolidated revenues rose nearly 7% compared with Q3 a year ago. However, total revenues fell $20 million short of consensus estimates of $8.20 billion. International markets led the revenue gains, with sales up 9% driven by double-digit growth in Latin America and Asia Pacific. The established medical devices and diagnostics segments each posted mid-single-digit revenue growth, offsetting a modest decline in established pharmaceuticals.

As Abbott approaches its Q4 earnings release, analysts forecast revenue growth of 5% to 6% for the quarter, with adult nutrition contributing an incremental 50 to 70 basis points. Management has signaled that investments in manufacturing capacity for Ensure and Glucerna would be fully online by year-end, potentially alleviating past supply constraints. With the stock essentially flat over the last 15 months—underperforming the S&P 500’s 17.5% total return—investors will be watching guidance closely for signs that margin expansion in high-growth markets and faster adoption of new nutritional products can propel a re-rating of the shares.